{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T12:38:21Z","timestamp":1785328701476,"version":"3.55.0"},"reference-count":46,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,3,24]],"date-time":"2022-03-24T00:00:00Z","timestamp":1648080000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Aim<\/jats:title><jats:p>The aim of this study was to investigate the association of endocrine complications after ICI immunotherapy with progression-free survival (PFS) and overall survival (OS) in a large single-center oncological cohort.<\/jats:p><\/jats:sec><jats:sec><jats:title>Patients and Methods<\/jats:title><jats:p>In total, 351 patients were included in the analysis, 248 men (70.7%) and 103 women (29.3%). The median age was 66 years. Patients had a variety of cancer types, namely, bladder cancer (131, 37.3%), renal cancer (89, 25.4%), lung cancer (74, 21.1%), ovarian cancer (22, 6.3%), and other types of cancer (35, 10%). The majority (314, 89.4%) were classified as stage IV, while 10.6% (37) were classified as stage III. Most of the patients received immunotherapy with anti-PD1 agents (262, 74.6%) and the rest with anti-PD-L1 agents (89, 25.4%). Kaplan\u2013Meier estimates were used to describe and visualize the effect of categorical variables on OS and PFS. Survival analysis was performed by Kaplan\u2013Meier curves, and survival differences between groups were estimated using the log-rank test. The estimation of the prognostic value of several variables with patients\u2019 survival was made by Cox regression models.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In total, 68 (19.4%) of patients presented an endocrine complication after immunotherapy with ICIs. Specifically, 66 (18.8%) had thyroid dysfunction, 1 patient presented hypophysitis (0.3%), and 1 patient had a combination of thyroid dysfunction and hypophysitis (0.3%). Patients with an endocrine complication had mPFS of 15 months (95% CI 11.0\u201318.9 months), while in those without endocrine complication mPFS was 7 months (95% CI 6.1\u20137.9 months, <jats:italic>p<\/jats:italic> &amp;lt; 0.001). Similarly, median OS (mOS) was statistically significant lower in the patients\u2019 group without endocrine complication. In fact, mOS was 51 months (95% CI 39.3\u201362.7 months) for these patients. The presence of endocrine complications after immunotherapy with ICIs retained its significance in terms of longer PFS (HR 0.57, 95% CI 0.39\u20130.81) and OS (HR 0.53, 95% CI 0.32\u20130.90) after multivariate analysis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>ICI endocrinopathies may be a positive predictor of immunotherapy response.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2022.847917","type":"journal-article","created":{"date-parts":[[2022,3,29]],"date-time":"2022-03-29T02:35:36Z","timestamp":1648521336000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":21,"title":["Oncological Patients With Endocrine Complications After Immunotherapy With Checkpoint Inhibitors Present Longer Progression-Free and Overall Survival"],"prefix":"10.3389","volume":"12","author":[{"given":"Stavroula A.","family":"Paschou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Liontos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evangelos","family":"Eleftherakis-Papaiakovou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katerina","family":"Stefanaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christos","family":"Markellos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos","family":"Koutsoukos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flora","family":"Zagouri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodora","family":"Psaltopoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meletios-Athanasios","family":"Dimopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,3,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3239","article-title":"The Blockade of Immune Checkpoints in Cancer Immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"B2","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1210\/er.2018-00006","article-title":"Endocrine Toxicity of Cancer Immunotherapy Targeting Immune Checkpoints","volume":"40","author":"Chang","year":"2019","journal-title":"Endocr Rev"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2020.1811226","article-title":"Safety Evaluation of Immune-Based Combinations in Patients With Advanced Renal Cell Carcinoma: A Systematic Review and Meta-Analysis","volume":"19","author":"Massari","year":"2020","journal-title":"Expert Opin Drug Saf"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2021.06.015","article-title":"Immune-Based Combinations for the Treatment of Metastatic Renal Cell Carcinoma: A Meta-Analysis of Randomised Clinical Trials","volume":"154","author":"Massari","year":"2021","journal-title":"Eur J Cancer"},{"key":"B5","doi-asserted-by":"publisher","first-page":"100328","DOI":"10.1016\/j.ctarc.2021.100328","article-title":"Biochemical Predictors of Response to Immune Checkpoint Inhibitors in Unresectable Hepatocellular Carcinoma","volume":"27","author":"Rizzo","year":"2021","journal-title":"Cancer Treat Res Commun"},{"key":"B6","doi-asserted-by":"publisher","first-page":"100011","DOI":"10.1016\/j.esmoop.2020.100011","article-title":"How We Treat Endocrine Complications of Immune Checkpoint Inhibitors","volume":"6","author":"Paschou","year":"2021","journal-title":"ESMO Open"},{"key":"B7","doi-asserted-by":"publisher","first-page":"2033","DOI":"10.3390\/jcm9072033","article-title":"Endocrinopathies Associated With Immune Checkpoint Inhibitor Cancer Treatment: A Review","volume":"9","author":"Okura","year":"2020","journal-title":"J Clin Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.3064","article-title":"Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-Analysis","volume":"4","author":"Barroso-Sousa","year":"2018","journal-title":"JAMA Oncol"},{"key":"B9","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE)2017"},{"key":"B10","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1038\/s41571-021-00508-x","article-title":"Beneficial Autoimmunity Improves Cancer Prognosis","volume":"18","author":"Zitvogel","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1186\/s12885-020-07142-3","article-title":"Correlation Between Immune-Related Adverse Events and Prognosis in Patients With Various Cancers Treated With Anti PD-1 Antibody","volume":"20","author":"Matsuoka","year":"2020","journal-title":"BMC Cancer"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.5012","article-title":"Multisystem Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Treatment of Non-Small Cell Lung Cancer","volume":"6","author":"Shankar","year":"2020","journal-title":"JAMA Oncol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/s12916-020-01549-2","article-title":"Are Immune-Related Adverse Events Associated With the Efficacy of Immune Checkpoint Inhibitors in Patients With Cancer? A Systematic Review and Meta-Analysis","volume":"18","author":"Zhou","year":"2020","journal-title":"BMC Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.192461099","article-title":"Involvement of PD-L1 on Tumor Cells in the Escape From Host Immune System and Tumor Immunotherapy by PD-L1 Blockade","volume":"99","author":"Iwai","year":"2002","journal-title":"Proc Natl Acad Sci USA"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-018-2819-x","article-title":"Immune-Related Adverse Events Correlate With Improved Survival in\u00a0Patients Undergoing Anti-PD1 Immunotherapy for Metastatic Melanoma","volume":"145","author":"Indini","year":"2019","journal-title":"J Cancer Res Clin Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2018.08.008","article-title":"Incidence, Risk Factors, and Effect on Survival of Immune Related Adverse Events in Patients With Non\u2013Small-Cell Lung Cancer","volume":"19","author":"Owen","year":"2018","journal-title":"Clin Lung Cancer"},{"key":"B17","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.clinthera.2018.11.004","article-title":"Association Between Immune-Related Adverse Events and Clinical Efficacy in Patients With Melanoma Treated With Nivolumab: A Multicenter Retrospective Study","volume":"41","author":"Okada","year":"2019","journal-title":"Clin Ther"},{"key":"B18","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/s40425-019-0579-z","article-title":"Real-World Efficacy and Safety of Nivolumab in Previously-Treated Metastatic Renal Cell Carcinoma, and Association Between Immune-Related Adverse Events and Survival: The Italian Expanded Access Program","volume":"7","author":"Verzoni","year":"2019","journal-title":"Cancer Sci"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.31629","article-title":"High-Dose Glucocorticoids for the Treatment of Ipilimumabinduced Hypophysitis Is Associated With Reduced Survival in Patients With Melanoma","volume":"124","author":"Faje","year":"2018","journal-title":"Cancer"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-1136","article-title":"Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association With Outcomes","volume":"22","author":"Freeman-Keller","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.2925","article-title":"Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non-Small Cell Lung Cancer","volume":"4","author":"Haratani","year":"2018","journal-title":"JAMA Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2017.1375642","article-title":"Development of Thyroid Dysfunction is Associated With Clinical Response to PD-1 Blockade Treatment in Patients With Advanced Non-Small Cell Lung Cancer","volume":"7","author":"Kim","year":"2017","journal-title":"Oncoimmunology"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw640","article-title":"Antibody-Mediated Thyroid Dysfunction During T-Cell Checkpoint Blockade in Patients With Non-Smallcell Lung Cancer","volume":"28","author":"Osorio","year":"2017","journal-title":"Ann Oncol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"e0216954","DOI":"10.1371\/journal.pone.0216954","article-title":"Incidence, Features, and Prognosis of Immune-Related Adverse Events Involving the Thyroid Gland Induced by Nivolumab","volume":"14","author":"Yamauchi","year":"2019","journal-title":"Immunotherapy"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2018.10.002","article-title":"Association Between Immune-Related Adverse Events and Efficacy of Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer","volume":"20","author":"Grangeon","year":"2018","journal-title":"Clin Lung Cancer"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-018-2805-3","article-title":"Impact of Immune-Related Adverse Events on Survival in Patients With Advanced Non-Small Cell Lung Cancer Treated With Nivolumab: Long-Term Outcomes From a Multi-Institutional Analysis","volume":"145","author":"Ricciuti","year":"2019","journal-title":"J Cancer Res Clin Oncol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1177\/1078155219829813","article-title":"Evaluation of the Impact of Thyroiditis Development in Patients Receiving Immunotherapy With Programmed Cell Death-1 Inhibitors","volume":"25","author":"Lei","year":"2019","journal-title":"J Oncol Pharm Pract"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2019.03.003","article-title":"Association Between Immune-Related Adverse Events and Prognosis in Patients With Metastatic Renal Cell Carcinoma Treated With Nivolumab","volume":"37","author":"Ishihara","year":"2019","journal-title":"Urol Oncol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.5860","article-title":"Profiling Preexisting Antibodies in Patients Treated With Anti-PD-1 Therapy for Advanced Non-Small Cell Lung Cancer","volume":"5","author":"Toi","year":"2018","journal-title":"JAMA Oncol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2019.02.006","article-title":"Correlations Between the Immune-Related Adverse Events Spectrum and Efficacy of Anti-PD1 Immunotherapy in NSCLC Patients","volume":"20","author":"Cortellini","year":"2019","journal-title":"Eurasian J Med"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.0402","article-title":"Association of Checkpoint Inhibitorinduced Toxic Effects With Shared Cancer and Tissue Antigens in Non-Small Cell Lung Cancer","volume":"5","author":"Berner","year":"2019","journal-title":"JAMA Oncol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-019-02899-y","article-title":"Comprehensive Analysis of the Characteristics and Treatment Outcomes of Patients With Non-Small Cell Lung Cancer Treated With Anti-PD-1 Therapy in Real-World Practice","volume":"145","author":"Ahn","year":"2019","journal-title":"J Cancer Res Clin Oncol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.13520","article-title":"Correlation Between Vitiligo Occurrence and Clinical Benefit in Advanced Melanoma Patients Treated With Nivolumab: A Multi-Institutional Retrospective Study","volume":"44","author":"Nakamura","year":"2017","journal-title":"J Dermatol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2017-0133","article-title":"Immune-Related Adverse Events as a Biomarker in Non-Melanoma Patients Treated With Programmed Cell Death 1 Inhibitors","volume":"22","author":"Judd","year":"2017","journal-title":"Oncologist"},{"key":"B35","doi-asserted-by":"publisher","first-page":"e97","DOI":"10.1016\/j.cllc.2018.09.005","article-title":"Efficacy of Nivolumab and Pembrolizumab in Patients With Advanced Non\u2013Small-Cell Lung Cancer Needing Treatment Interruption Because of Adverse Events: A Retrospective Multicenter Analysis","volume":"20","author":"Ksienski","year":"2019","journal-title":"Clin Lung Cancer"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2018.10.014","article-title":"Immune-Related Adverse Events Predict the Therapeutic Efficacy of Anti\u2013PD-1 Antibodies in Cancer Patients","volume":"109","author":"Rogado","year":"2019","journal-title":"Eur J Cancer"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.1825","article-title":"Safety of Combined PD-1 Pathway Inhibition and Radiation Therapy for Non-Small-Cell Lung Cancer: A Multicentric Retrospective Study From the GFPC","volume":"7","author":"Lesueur","year":"2018","journal-title":"Cancer Med"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-17-0063","article-title":"Treatment-Related Adverse Events Predict Improved Clinical Outcome in NSCLC Patients on KEYNOTE-001 at a Single Center","volume":"6","author":"Lisberg","year":"2018","journal-title":"Cancer Immunol Res"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1080\/0284186X.2019.1615636","article-title":"Efficacy and Safety of Immune Checkpoint Inhibitors in a Danish Real Life Non-Small Cell Lung Cancer Population: A Retrospective Cohort Study","volume":"58","author":"Bj\u00f8rnhart","year":"2019","journal-title":"Acta Oncol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2018-0146","article-title":"Clinical Significance of Signs of Autoimmune Colitis in (18)F-Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography of 100 Stage-IV Melanoma Patients","volume":"11","author":"Lang","year":"2019","journal-title":"Immunotherapy"},{"key":"B41","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.lungcan.2018.02.017","article-title":"Efficacy and Safety of Nivolumab in Previously Treated Patients With Non-Small Cell Lung Cancer: A Multicenter Retrospective Cohort Study","volume":"119","author":"Fujimoto","year":"2018","journal-title":"Lung Cancer"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2017.11.019","article-title":"Correlation Between Immune-Related Adverse Events and Efficacy in Non-Small Cell Lung Cancer Treated With Nivolumab","volume":"115","author":"Sato","year":"2018","journal-title":"Lung Cancer"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2015.1916","article-title":"Pembrolizumab Cutaneous Adverse Events and Their Association With Disease Progression","volume":"151","author":"Sanlorenzo","year":"2015","journal-title":"JAMA Dermatol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1158\/2326-6066.CIR-18-0245","article-title":"Autoantibody Development Under Treatment With Immune-Checkpoint Inhibitors","volume":"7","author":"de Moel","year":"2019","journal-title":"Cancer Immunol Res"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.66.1389","article-title":"Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma","volume":"35","author":"Weber","year":"2017","journal-title":"J Clin Oncol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.60.8448","article-title":"Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center","volume":"33","author":"Horvat","year":"2015","journal-title":"J Clin Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.847917\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,29]],"date-time":"2022-03-29T02:35:43Z","timestamp":1648521343000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.847917\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,24]]},"references-count":46,"alternative-id":["10.3389\/fonc.2022.847917"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2022.847917","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,24]]},"article-number":"847917"}}